Fear, anecdotal evidence influence patients' decisions about prostate cancer treatment

Prostate cancer patients make treatment decisions that are influenced by anecdote and misconception rather than clinical trial evidence, according to a study by researchers at the University of Colorado Health Sciences Center, Denver.

Related Videos

Joseph Song, MD, on the emergence of new suction-based devices for stone disease

How eating disorders affect bladder and pelvic floor health

Fitting Oral ADT Options Into the Prostate Cancer Treatment Plans

The Current Landscape of ADT in Prostate Cancer

Daniel D. Joyce, MD, MS, discusses the economics of trimodal therapy in MIBC

Sarah Razavi, MD, outlines strategies for mitigate surgeon discomfort during URS

Can ctDNA detect molecular residual disease in NMIBC?

Expert discusses setting realistic expectations for Rezum for BPH

Considering Therapy De-Intensification: Balancing Adverse Effects and PSA Response

Nicolette G. Payne, MD, discusses risk factors for burnout among pediatric urologists

Related Content

Advertisement

July 24th 2025

Aquablation procedures for prostate cancer completed at ambulatory surgery center

Hannah Clarke

The WATER IV PCa trial is comparing first-line Aquablation therapy with radical prostatectomy for the treatment of patients with localized prostate cancer.

July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

July 23rd 2025

FDA clears image-guided navigation platform for focal therapy in prostate cancer

Hannah Clarke

The new advanced annotation workflow on the UroNav System is designed to work in tandem with DynaCAD Urology to support focal therapy planning.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 23rd 2025

When to report 50320 with 49187 for nephrectomy procedures

Jonathan Rubenstein, MD Mark Painter

"As always, we encourage you to communicate among all team members and pay attention to your documentation," write Jonathan Rubenstein, MD, and Mark Painter.

Published: July 22nd 2025 | Updated: July 23rd 2025

Irreversible electroporation with NanoKnife found safe, effective for prostate tissue ablation

Hannah Clarke

The PRESERVE trial met its primary end point by demonstrating a negative in-field biopsy rate of 71% at 12 months.

Related Content

Advertisement

July 24th 2025

Aquablation procedures for prostate cancer completed at ambulatory surgery center

Hannah Clarke

The WATER IV PCa trial is comparing first-line Aquablation therapy with radical prostatectomy for the treatment of patients with localized prostate cancer.

July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

July 23rd 2025

FDA clears image-guided navigation platform for focal therapy in prostate cancer

Hannah Clarke

The new advanced annotation workflow on the UroNav System is designed to work in tandem with DynaCAD Urology to support focal therapy planning.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 23rd 2025

When to report 50320 with 49187 for nephrectomy procedures

Jonathan Rubenstein, MD Mark Painter

"As always, we encourage you to communicate among all team members and pay attention to your documentation," write Jonathan Rubenstein, MD, and Mark Painter.

Published: July 22nd 2025 | Updated: July 23rd 2025

Irreversible electroporation with NanoKnife found safe, effective for prostate tissue ablation

Hannah Clarke

The PRESERVE trial met its primary end point by demonstrating a negative in-field biopsy rate of 71% at 12 months.